{
    "id": 5520,
    "fullName": "FLT3 D835X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 D835X indicates any Flt3 missense mutation that results in the aspartic acid (D) at amino acid 835 being replaced by a different amino acid. FLT3 codon 835 mutations are \"hotspot\" mutations that often result in constitutive phosphorylation of Flt3 and activation of downstream signaling (PMID: 11290608, PMID: 15256420) and therefore, are predicted to lead to a gain of Flt3 protein function.",
            "references": [
                {
                    "id": 2011,
                    "pubMedId": 11290608,
                    "title": "Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11290608"
                },
                {
                    "id": 2706,
                    "pubMedId": 15256420,
                    "title": "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256420"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "D835X",
    "createDate": "04/28/2015",
    "updateDate": "11/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 144452,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28018503_28018505",
        "cDna": "c.2503_2505",
        "protein": "p.D835",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19041,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "FLT3 D835 mutations are associated with poor prognosis in patients with myelodysplastic syndromes (NCCN.org).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50908,
                "name": "myelodysplastic syndrome",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17425,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD), D835, or I836 mutation (FDA.gov; NCT02421939).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15484,
                    "pubMedId": null,
                    "title": "Xospata (gilteritinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6884,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5948,
                    "pubMedId": null,
                    "title": "Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.",
                    "url": "http://meetinglibrary.asco.org/content/170782-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17421,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant (D835X and I836X) or FLT3-ITD (exon 14 insertions) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 3137,
                "therapyName": "Cytarabine + Daunorubicin + Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9261,
                    "pubMedId": 28644114,
                    "title": "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28644114"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15482,
                    "pubMedId": null,
                    "title": "Rydapt (midostaurin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12563,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 3189,
                "therapyName": "Selinexor + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10434,
                    "pubMedId": null,
                    "title": "a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper107872.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19766,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia cells harboring FLT3 D835X demonstrated sensitivity to LAM-003 treatment in culture (PMID: 31751472).",
            "molecularProfile": {
                "id": 5329,
                "profileName": "FLT3 D835X"
            },
            "therapy": {
                "id": 7362,
                "therapyName": "LAM-003",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17544,
                    "pubMedId": 31751472,
                    "title": "LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31751472"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6886,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 128 days in AML patients harboring both FLT3 D835X and exon 14 insertion (ITD) that received no prior therapy, and an OS of 63 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",
            "molecularProfile": {
                "id": 23954,
                "profileName": "FLT3 exon 14 ins FLT3 D835X"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5948,
                    "pubMedId": null,
                    "title": "Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.",
                    "url": "http://meetinglibrary.asco.org/content/170782-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12564,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).",
            "molecularProfile": {
                "id": 23954,
                "profileName": "FLT3 exon 14 ins FLT3 D835X"
            },
            "therapy": {
                "id": 3189,
                "therapyName": "Selinexor + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10434,
                    "pubMedId": null,
                    "title": "a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper107872.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5329,
            "profileName": "FLT3 D835X",
            "profileTreatmentApproaches": [
                {
                    "id": 4222,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 D835X"
                }
            ]
        },
        {
            "id": 23954,
            "profileName": "FLT3 exon 14 ins FLT3 D835X",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144452,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28018503_28018505",
            "cDna": "c.2503_2505",
            "protein": "p.D835",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}